Aytu Biopharma (AYTU) Corporate presentation summary

Mission and therapeutic focus

• Focuses on improving patient lives, especially those with complex CNS conditions such as major depressive disorder (MDD) and ADHD.

• Portfolio includes novel therapeutics for MDD and ADHD, with additional pediatric products.

Product portfolio and innovation

• Features differentiated, patent-protected prescription brands, including EXXUA for MDD and Adzenys XR-ODT and Cotempla XR-ODT for ADHD.

• EXXUA is a first-in-class 5HT1A agonist for MDD, offering efficacy without common antidepressant side effects like sexual dysfunction or weight gain.

• ADHD and pediatric brands include unique formulations and first-to-market products.

Commercial strategy and infrastructure

• Utilizes the proprietary Aytu RxConnect® program to enhance patient access, adherence, and affordability.

• Lean, scalable commercial infrastructure with a direct sales force and analytics platform supports rapid expansion.

• Multi-faceted EXXUA launch strategy includes sales force promotion, virtual HCP engagement, and broad retail distribution.